Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
NCT03516981Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib, quavonlimab, favezelimab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03516981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516981.